Compare FSUN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | PCRX |
|---|---|---|
| Founded | 1892 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 966.0M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | FSUN | PCRX |
|---|---|---|
| Price | $36.63 | $22.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $44.00 | $37.60 |
| AVG Volume (30 Days) | 110.3K | ★ 801.0K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $77.96 | $9.77 |
| Revenue Next Year | $15.07 | $9.71 |
| P/E Ratio | ★ $11.30 | $138.44 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $29.95 | $18.80 |
| 52 Week High | $42.34 | $27.99 |
| Indicator | FSUN | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 52.21 |
| Support Level | $34.52 | $20.41 |
| Resistance Level | $40.09 | $23.91 |
| Average True Range (ATR) | 1.11 | 1.00 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 63.53 | 54.08 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.